Related Experiment Videos

Endothelin receptor antagonists in heart failure: current status and future directions

Georg Ertl1, Johann Bauersachs

  • 1Medizinische Klinik, Universität Würzburg, Wuerzburg, Germany. ertl_g@klinik.uni-wuerzburg.de

Drugs
|May 14, 2004
PubMed

Insights

Endothelin antagonists show promise for heart failure but long-term use and specific receptor targeting require further investigation. More research is needed to clarify their role in left ventricular remodelling.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Endothelin (ET)-1 is implicated in left ventricular remodelling and heart failure progression.
  • Elevated plasma ET-1 levels correlate with heart failure severity.
  • Upregulated endothelin and its receptors are observed in failing hearts.

Purpose of the Study:

  • To evaluate the efficacy of endothelin antagonists in heart failure.
  • To investigate the long-term effects of ET antagonists on cardiovascular parameters and left ventricular remodelling.
  • To explore reasons for the limited success of current endothelin antagonist therapies.

Main Methods:

  • Review of experimental evidence and clinical trials on endothelin antagonists.
  • Analysis of studies involving nonselective and selective ET-A/ET-B receptor antagonists.
  • Assessment of data from the Endothelin-A Receptor Antagonist Trial in Heart Failure (EARTH).

Main Results:

  • Short-term endothelin antagonist treatment improved haemodynamics in heart failure patients.
  • Long-term treatment did not significantly improve morbidity/mortality endpoints.
  • The selective ET-A antagonist darusentan showed no significant effect on left ventricular remodelling in the EARTH trial.

Conclusions:

  • Long-term endothelin antagonist therapy has not demonstrated significant clinical benefit in heart failure.
  • Potential limitations include adverse effects on healing and an unclear role of ET-B receptors.
  • Further studies in specific patient populations, like those post-myocardial infarction, are warranted.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...